Table 3.
Detailed treatment description of patients
| Pt. | Comb. partner |
6-wk |
12-wk |
PFS (d) | OS (d) | ||
| Response | % change | Response | % change | ||||
| 1 | 5-FU | SD | -13% | SD | -7% | 144 | 165 |
| 2 | None | 0 | 0 | 0 | 0 | 21 | 21 |
| 3 | TU | SD | 12% | 0 | 0 | 791 | 163 |
| 4 | 5-FU | PD | 35% | 0 | 0 | 41 | 382 |
| 5 | C | SD | -6% | PD | 32% | 149 | 302 |
| 6 | TU | SD | -2% | 0 | 0 | 322 | 113 |
| 7 | C | SD | -21% | SD | 5% | 137 | 188 |
| 8 | C | SD | -4% | PD | 24% | 199 | 296 |
| 9 | C | SD | 3% | PD | 32% | 177 | 147 |
| 10 | TU | SD | 5% | SD | 6% | 188 | 447 |
1
Treatment stop due to bleeding complication;
2
Treatment stop due to sorafenib allergy. TU: Tegafur Uracil; C: Capecitabine; SD: Stable disease; PD: Progressive disease; PFS: Progression free survival.